Steve O'Loughlin - Sep 1, 2021 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Role
Chief Financial Officer
Signature
/s/ Steve O'Loughlin
Stock symbol
ATNM
Transactions as of
Sep 1, 2021
Transactions value $
$0
Form type
4
Date filed
9/3/2021, 05:02 PM
Next filing
Jul 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNM Stock Option (Right to Buy) Award $0 +107K $0.00 107K Sep 1, 2021 Common Stock 107K $6.07 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.
F2 Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.